Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

Valeant Will Pay $96.25 Million to Resolve the LitigationLAVAL, Quebec, Dec. 29, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced the parties in the cases of Basile v. Valeant Pharmaceuticals...